The Board of Directors of Ascendis has authorized a $120M share repurchase program.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating
- Ascendis Pharma price target raised to $322 from $297 at Wells Fargo
- Ascendis Pharma Posts Strong Year-Long Phase 2 COACH Data for TransCon CNP and hGH Combo in Achondroplasia
- Ascendis Pharma: Advancing Achondroplasia Combo Franchise and De-Risked Regulatory Path Support Buy Rating and $242 Target
- Ascendis Pharma announces topline results from Week 52 of COACH trial